{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:40:57Z","timestamp":1778701257396,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1053\/j.seminoncol.2020.10.003","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T00:44:06Z","timestamp":1603500246000},"page":"361-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Combination therapy in metastatic renal cell carcinoma: Back to the future?"],"prefix":"10.1053","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-244X","authenticated-orcid":false,"given":"Luigi","family":"Cerbone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Cattrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Vallome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Maddalena","family":"Latocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Boccardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-4226","authenticated-orcid":false,"given":"Elisa","family":"Zanardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2020.10.003_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA. Cancer J. Clin."},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ucl.2008.07.005","article-title":"Epidemiology, Clinical Staging, and Presentation of Renal Cell Carcinoma","volume":"35","author":"DeCastro","year":"2008","journal-title":"Urol. Clin. North Am"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0003","unstructured":"Lane Brian R, Canter Daniel J, Rini Brian I, Uzzo Robert C. Cancer of the Kidney, In: DeVita, Hellman, and Rosenberg's Cancer Principles & Practice of Oncology. 2015, p. 865\u201382."},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0004","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0005","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. IFN-Alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma 8. doi: 10.1200\/JCO.2002.20.1.289. PMID: 11773181.","DOI":"10.1200\/JCO.2002.20.1.289"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0006","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/ng0594-85","article-title":"Mutations of the VHL tumour suppressor gene in renal carcinoma","volume":"7","author":"Gnarra","year":"1994","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0007","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/01.ju.0000074870.54671.98","article-title":"Overproduction of Vascular Endothelial Growth Factor Related to von Hippel-Lindau Tumor Suppressor Gene Mutations and Hypoxia-Inducible Factor-1\u03b1 Expression in Renal Cell Carcinomas","volume":"170","author":"Na","year":"2003","journal-title":"J. Urol."},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0008","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2020.10.003_bib0009","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2020.10.003_bib0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminoncol.2020.10.003_bib0011","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9807","key":"10.1053\/j.seminoncol.2020.10.003_bib0012","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"30","key":"10.1053\/j.seminoncol.2020.10.003_bib0013","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial","volume":"31","author":"Motzer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminoncol.2020.10.003_bib0014","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/1756287217713902","article-title":"Sunitinib in the treatment of renal cell carcinoma: an up- 326 date on recent evidence","volume":"9","author":"Rizzo","year":"2017","journal-title":"Ther Adv Urol"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0016","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"issue":"9637","key":"10.1053\/j.seminoncol.2020.10.003_bib0017","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"22","key":"10.1053\/j.seminoncol.2020.10.003_bib0018","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.seminoncol.2020.10.003_bib0019","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0020","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant Human Interleukin-2, Recombinant Human IFN Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma","volume":"338","author":"Negrier","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0021","doi-asserted-by":"crossref","unstructured":"Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus IFN alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, 2007;370, 9.","DOI":"10.1016\/S0140-6736(07)61904-7"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0022","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus IFN alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0023","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab Plus IFN Alfa Compared With IFN Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0024","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0025","first-page":"61","article-title":"NCCN Guidelines Index Table of Contents Discussion","author":"Motzer","year":"2019","journal-title":"Kidney Cancer"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0026","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2009.26.3152","article-title":"Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma","volume":"28","author":"Hainsworth","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0027","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/annonc\/mdv170","article-title":"RECORD-2: phase II randomized study of everolimus and bevacizumab versus IFN \u03b1-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma","volume":"26","author":"Ravaud","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0028","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or IFN alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial","volume":"12","author":"N\u00e9grier","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0029","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.2013.50.5305","article-title":"Randomized phase III trial of temsirolimus and bevacizumab versus IFN alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial","volume":"32","author":"Rini","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0030","first-page":"3851","article-title":"Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study","volume":"35","author":"Hammers","year":"2017","journal-title":"Saf. Effic. Nivolumab Comb. Ipilimumab Metastatic Ren. Cell Carcinoma CheckMate 016 Study"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0031","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0032","doi-asserted-by":"crossref","first-page":"abstr 547","DOI":"10.1200\/JCO.2019.37.7_suppl.547","article-title":"Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab\u202f+\u202fipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"37","author":"Tannir","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0420-0","article-title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","volume":"6","author":"Amin","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0034","doi-asserted-by":"crossref","first-page":"abstr 4506","DOI":"10.1200\/JCO.2017.35.15_suppl.4506","article-title":"A phase I\/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"35","author":"Chowdury","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0035","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00262-018-2136-x","article-title":"The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models","volume":"67","author":"L\u00e4ubli","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1053\/j.seminoncol.2020.10.003_bib0036","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2020.10.003_bib0037","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"KEYNOTE-426 Investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2020.10.003_sbref0038","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377542030110X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377542030110X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:55:31Z","timestamp":1758804931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377542030110X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S009377542030110X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2020.10.003","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy in metastatic renal cell carcinoma: Back to the future?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2020.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}